ESR1 and breast carcinoma: Inhibition of GART by siRNA-mediated depletion or lometrexol (LMX) inhibitor preferentially reduced cell proliferation and induced ERα degradation in ERα-positive IDC cell lines belonging to the LumA clinical surrogate class of breast cancer.